Iterum Therapeutics plc (ITRM)
NASDAQ: ITRM · Real-Time Price · USD
1.659
+0.029 (1.75%)
Nov 21, 2024, 11:34 AM EST - Market open
Iterum Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2016 |
| Revenue | - | - | - | - | - | 0.04 | Upgrade
|
| Revenue Growth (YoY) | - | - | - | - | - | -95.74% | Upgrade
|
| Gross Profit | - | - | - | - | - | 0.04 | Upgrade
|
| Selling, General & Admin | 7.55 | 7.48 | 12.77 | 13.83 | 11.05 | 11.28 | Upgrade
|
| Research & Development | 18.9 | 39.99 | 17.62 | 10.71 | 21.07 | 90.77 | Upgrade
|
| Operating Expenses | 26.46 | 47.47 | 30.38 | 24.54 | 32.13 | 102.06 | Upgrade
|
| Operating Income | -26.46 | -47.47 | -30.38 | -24.54 | -32.13 | -102.02 | Upgrade
|
| Interest Expense | -3.78 | -3.15 | -3.18 | -4.53 | -12.3 | -1.76 | Upgrade
|
| Interest & Investment Income | 1.72 | 1.72 | 0.82 | - | - | 0.9 | Upgrade
|
| Other Non Operating Income (Expenses) | -1.69 | 11.14 | -11.39 | -61.79 | -7.18 | 0.2 | Upgrade
|
| EBT Excluding Unusual Items | -30.2 | -37.76 | -44.13 | -90.86 | -51.6 | -102.69 | Upgrade
|
| Other Unusual Items | - | - | - | - | 0.34 | - | Upgrade
|
| Pretax Income | -30.2 | -37.76 | -44.13 | -90.86 | -51.26 | -102.69 | Upgrade
|
| Income Tax Expense | 0.36 | 0.61 | 0.3 | 0.71 | 0.74 | 0.44 | Upgrade
|
| Net Income | -30.55 | -38.37 | -44.43 | -91.56 | -52.01 | -103.13 | Upgrade
|
| Net Income to Common | -30.55 | -38.37 | -44.43 | -91.56 | -52.01 | -103.13 | Upgrade
|
| Shares Outstanding (Basic) | 16 | 13 | 12 | 11 | 2 | 1 | Upgrade
|
| Shares Outstanding (Diluted) | 16 | 13 | 12 | 11 | 2 | 1 | Upgrade
|
| Shares Change (YoY) | 28.02% | 5.93% | 12.35% | 580.42% | 65.38% | 66.22% | Upgrade
|
| EPS (Basic) | -1.87 | -2.96 | -3.63 | -8.41 | -32.49 | -106.55 | Upgrade
|
| EPS (Diluted) | -1.87 | -2.96 | -3.63 | -8.41 | -32.49 | -106.55 | Upgrade
|
| Free Cash Flow | - | -39.34 | -18.54 | -15.9 | -54.54 | -81.95 | Upgrade
|
| Free Cash Flow Per Share | - | -3.04 | -1.51 | -1.46 | -34.07 | -84.67 | Upgrade
|
| Gross Margin | - | - | - | - | - | 100.00% | Upgrade
|
| Operating Margin | - | - | - | - | - | -275732.43% | Upgrade
|
| Profit Margin | - | - | - | - | - | -278729.73% | Upgrade
|
| Free Cash Flow Margin | - | - | - | - | - | -221475.68% | Upgrade
|
| EBITDA | -25.99 | -45.72 | -28.58 | -22.43 | -31.97 | -101.87 | Upgrade
|
| D&A For EBITDA | 0.46 | 1.75 | 1.8 | 2.1 | 0.16 | 0.15 | Upgrade
|
| EBIT | -26.46 | -47.47 | -30.38 | -24.54 | -32.13 | -102.02 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.